Loading stock data…
Arcturus Therapeutics Holdings (ARCT)
$15.82+0.26 (+1.67%)
Pre-Market$15.68-0.14 (-0.88%)· Last close Sep 4
Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Arcturus Therapeutics Holdings Inc. in the Healthcare sector is trading at $15.82 with a market capitalization of $450M. Wall Street consensus targets $22.30 (10 analysts), implying a +41.0% move over the next 12 months. The stock is currently 35% below its 52-week high of $24.17, remaining 103.9% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +41.0% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $880,000↑ | $610,000↓ | $3.08M↓ | $14.15M↓ | $24.51M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$25.55M↑ | -$28.93M↑ | -$31.31M↓ | -$16.51M↓ | -$11.62M |
| Net Income | -$23.79M↑ | -$26.96M↑ | -$29.08M↓ | -$13.45M↓ | -$9.18M |
Peer Comparison
JNJUNHPFE
Fundamentals
Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a li...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$449.65M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.48
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-54.29%
Volume
Today's trading volume
534,617
Recent News
Arcturus Therapeutics (ARCT) Just Flashed Golden Cross Signal: Do You Buy?
Is it a good or bad thing when a stock experiences a golden cross technical event?
Can mRNA Cure Cancer? Inside the Pipeline Risks for Biotech’s Biggest Players
The success of Moderna and Merck’s intismeran autogene doesn’t guarantee smooth sailing for other mRNA vaccine developers
Moderna And Merck's Cancer Vaccine: Are Investors Putting The Cart Before The Horse?
Moderna and Merck scored a big win for their cancer vaccine on Wednesday. But analysts say it's too early to call it a home run.
Arcturus Therapeutics Eyes Phase III CF Call, OTC Data as Vaccine Funds Pipeline
Arcturus Therapeutics (NASDAQ:ARCT) is positioning its mRNA platform around two rare-disease programs targeting cystic fibrosis and ornithine transcarbamylase deficiency, while its vaccine business is intended to help support therapeutic development, President and CEO Joseph Payne said during a Cana
Arcturus Therapeutics Q2 Earnings Call Highlights
Arcturus Therapeutics (NASDAQ:ARCT) reported progress across its rare-disease pipeline during the second quarter of 2026, completed enrollment and dosing in its Phase II ornithine transcarbamylase deficiency study, and regained global rights to its KOSTAIVE COVID-19 vaccine and self-amplifying mRNA